A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007

Phase Ii ◽

Medroxyprogesterone Acetate ◽

Hormone Receptor ◽

Phase Ii Study ◽

Metastatic Breast ◽

Breast Cancer Research ◽

Research Consortium

A phase II study of medroxyprogesterone acetate (MPA) in patients (pts) with hormone receptor-negative (HR-) metastatic breast cancer (MBC): Translational Breast Cancer Research Consortium trial 007.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.1074 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 1074-1074

Author(s):

L. G. Vaughn ◽

L. Li ◽

L. Nabell ◽

H. S. Rugo ◽

L. A. Carey ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Research ◽

Phase Ii ◽

Medroxyprogesterone Acetate ◽

Hormone Receptor ◽

Phase Ii Study ◽

Metastatic Breast ◽

Breast Cancer Research ◽

Research Consortium

Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study

British Journal of Cancer ◽

10.1038/sj.bjc.6601840 ◽

2004 ◽

Vol 90 (11) ◽

pp. 2131-2134 ◽

Cited By ~ 3

Author(s):

A C Humphreys ◽

J Dent ◽

S Rodwell ◽

S M Crawford ◽

J K Joffe ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Research ◽

Phase Ii ◽

Research Group ◽

Phase Ii Study ◽

Metastatic Breast ◽

Breast Cancer Research ◽

Venous Infusion

A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-007-0497-5 ◽

2007 ◽

Vol 61 (3) ◽

pp. 509-514 ◽

Cited By ~ 34

Author(s):

Daigo Yamamoto ◽

Satoru Iwase ◽

Kaoru Kitamura ◽

Hiroki Odagiri ◽

Chizuko Yamamoto ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Research ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Breast Cancer Research ◽

Research Network ◽

Cancer Research Network

Randomised Phase II Study of Palbociclib Plus Exemestane with GnRH Agonist Versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer

SSRN Electronic Journal ◽

10.2139/ssrn.3414442 ◽

2019 ◽

Author(s):

Yeon Hee Park ◽

Tae-Yong Kim ◽

Gun Min Kim ◽

Kyung Hae Jung ◽

Seok Yun Kang ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Gnrh Agonist ◽

Hormone Receptor ◽

Phase Ii Study ◽

Metastatic Breast ◽

Premenopausal Women ◽

A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2020.01.012 ◽

2020 ◽

Vol 20 (3) ◽

pp. 238-245 ◽

Cited By ~ 2

Author(s):

Romualdo Barroso-Sousa ◽

Ian E. Krop ◽

Lorenzo Trippa ◽

Zhenying Tan-Wasielewski ◽

Tianyu Li ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Study ◽

Metastatic Breast ◽

Palliative Radiotherapy ◽

Hormonal Therapy Plus Bevacizumab in Postmenopausal Patients Who Have Hormone Receptor–Positive Metastatic Breast Cancer: A Phase II Trial of the Sarah Cannon Oncology Research Consortium

Clinical Breast Cancer ◽

10.1016/j.clbc.2011.03.010 ◽

2011 ◽

Vol 11 (3) ◽

pp. 146-152 ◽

Cited By ~ 21

Author(s):

Denise A. Yardley ◽

Howard A. Burris ◽

Bobby L. Clark ◽

Dianna Shipley ◽

Mark Rubin ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Hormonal Therapy ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Hormone Receptor Positive ◽

Oncology Research ◽

Research Consortium

129P Phase II study of pembrolizumab and nab-paclitaxel in HER2-negative metastatic breast cancer: Hormone receptor-positive cohort

Annals of Oncology ◽

10.1016/j.annonc.2020.03.232 ◽

2020 ◽

Vol 31 ◽

pp. S59

Author(s):

Y. Novik ◽

N. Klar ◽

S. Zamora ◽

M. Kwa ◽

J. Speyer ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Study ◽

Metastatic Breast ◽

Molecular marker correlates of clinical outcome in a phase II study of gefitinib or placebo in combination with anastrozole in postmenopausal women with hormone receptor-positive metastatic breast cancer.

10.1158/0008-5472.sabcs-3131 ◽

2009 ◽

Cited By ~ 2

Author(s):

V Valero ◽

S Bacus ◽

A Mangalik ◽

I Rabinowitz ◽

F Arena ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Outcome ◽

Molecular Marker ◽

Postmenopausal Women ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Study ◽

Metastatic Breast ◽

Abstract OT3-2-05: Randomized phase II study of fulvestrant with or without ganetespib in patients (pts) with hormone receptor (HR)-positive metastatic breast cancer

10.1158/0008-5472.sabcs13-ot3-2-05 ◽

2013 ◽

Author(s):

NU Lin ◽

L Whitesell ◽

R Gelman ◽

E Mayer ◽

IE Krop ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Study ◽

Metastatic Breast ◽

Randomized Phase Ii

Abstract OT2-6-10: DETECT IV – A multicenter, single arm, phase II study evaluating the efficacy of everolimus in combination with endocrine therapy in patients with HER2-negative, hormone-receptor positive metastatic breast cancer and HER2-negative circulating tumor cells (CTCs)

10.1158/0008-5472.sabcs13-ot2-6-10 ◽

2013 ◽

Author(s):

F Schochter ◽

C Melcher ◽

C Hagenbeck ◽

TWP Friedl ◽

B Jäger ◽

...

Keyword(s):

Breast Cancer ◽

Endocrine Therapy ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Study ◽

Metastatic Breast ◽